[1] Ahmed RM, Hodges JR, Piguet O. Behavioural variant frontotemporal dementia:recent advances in the diagnosis and understanding of the disorder[J]. Adv Exp Med Biol, 2021, 1281:1-15. [2] Peet BT, Spina S, Mundada N, La Joie R. Neuroimaging in frontotemporal dementia:heterogeneity and relationships with underlying neuropathology[J]. Neurotherapeutics, 2021, 18:728-752. [3] Zhou K, Yang F, Li Y, Chen Y, Zhang X, Zhang J, Wang J, Dai J, Cai L, Cui M. Synthesis and evaluation of fluorine-18 labeled 2-phenylquinoxaline derivatives as potential tau imaging agents[J]. Mol Pharm, 2021, 18:1176-1195. [4] Wang Y, Cai L, Zhou K, Cui M, Yao S. Biodistribution and dosimetry evaluation for a novel tau tracer[18F]-S16 in healthy volunteers and its application in assessment of tau pathology in Alzheimer's disease[J]. Front Bioeng Biotechnol, 2022, 9:812818. [5] Expert Consensus Writing Group on Frontotemporal Degeneration, Geriatric Neurology Group, Geriatric Branch, Chinese Medical Association. Expert consensus on frontotemporal degeneration[J]. Zhonghua Shen Jing Ke Za Zhi, 2014, 47:351-356.[中华医学会老年医学分会老年神经病学组额颞叶变性专家共识撰写组.额颞叶变性专家共识[J].中华神经科杂志, 2014, 47:351-356.] [6] Cai GJ, Zhang MY, Zhang SP, Wang JM, Zhou TX. Application validity of MMSE and BDRS[J]. Zhongguo Shen Jing Jing Shen Ji Bing Za Zhi, 1988, 14:298-299.[蔡国钧, 张明园, 张少平, 王纪明, 周天骍. MMSE和BDRS的应用效度[J].中国神经精神疾病杂志, 1988, 14:298-299.] [7] Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA:a brief screening tool for mild cognitive impairment[J]. J Am Geriatr Soc, 2005, 53:695-699. [8] Kong Y, Wu LY. Research progress of tau pet in frontotemporal dementia with MAPT gene mutation[J]. Shi Yong Yi Xue Za Zhi, 2020, 36:2157-2160.[孔雨, 武力勇. MAPT基因突变额颞叶痴呆tau蛋白靶向正电子发射计算机断层显像技术研究进展[J].实用医学杂志, 2020, 36:2157-2160.] [9] Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, Villemagne VL, Aisen P, Vendruscolo M, Iwatsubo T, Masters CL, Cho M, Lannfelt L, Cummings JL, Vergallo A. The amyloid-β pathway in Alzheimer's disease[J]. Mol Psychiatry, 2021, 26:5481-5503. [10] Zhang YD. A new classification of primary tau disese[J]. Lin Chuang Shen Jing Bing Xue Za Zhi, 2020, 33:401-406.[张颖冬.原发性Tau蛋白病的新分类[J].临床神经病学杂志, 2020, 33:401-406.] [11] Lin HM, Wu P, Zuo CT. Molecular imaging progress of positron emission tomography in frontotemporal dementia[J]. Zhongguo Lin Chuang Shen Jing Ke Xue, 2021, 29:686-689.[林华媚, 吴平, 左传涛.额颞叶痴呆的正电子发射断层显像分子影像学研究进展[J].中国临床神经科学, 2021, 29:686-689.] [12] Cai L, Wang Y, Yang HL, Li YS. Clinical research progress of 18F-AV1451 PET imaging in Alzheimer disease[J]. Guo Ji Fang She Yi Xue He Yi Xue Za Zhi, 2020, 44:507-514.[蔡莉, 王颖, 杨海磊, 李彦生. 18F-AV1451 PET在阿尔茨海默病中的临床研究进展[J].国际放射医学核医学杂志, 2020, 44:507-514.] [13] Nam G, Jeong HJ, Kang JM, Lee SY, Seo S, Seo HE, Park KH, Yeon BK, Ido T, Shin DJ, Noh Y. 18F-THK5351 PET imaging in the behavioral variant of frontotemporal dementia[J]. Dement Neurocogn Disord, 2018, 17:163-173. [14] Su Y, Fu J, Yu J, Zhao Q, Guan Y, Zuo C, Li M, Tan H, Cheng X. Tau PET imaging with[18F] PM-PBB3 in frontotemporal dementia with MAPT mutation[J]. J Alzheimers Dis, 2020, 76:149-157. [15] Beyer L, Nitschmann A, Barthel H, van Eimeren T, Unterrainer M, Sauerbeck J, Marek K, Song M, Palleis C, Respondek G, Hammes J, Barbe MT, Onur Ö, Jessen F, Saur D, Schroeter ML, Rumpf JJ, Rullmann M, Schildan A, Patt M, Neumaier B, Barret O, Madonia J, Russell DS, Stephens AW, Roeber S, Herms J, Bötzel K, Levin J, Classen J, Höglinger GU, Bartenstein P, Villemagne V, Drzezga A, Seibyl J, Sabri O, Brendel M. Early-phase[18F] PI-2620 tau-PET imaging as a surrogate marker of neuronal injury[J]. Eur J Nucl Med Mol Imaging, 2020, 47:2911-2922. [16] Whitwell JL. FTD spectrum:neuroimaging across the FTD spectrum[J]. Prog Mol Biol Transl Sci, 2019, 165:187-223. [17] Tracy TE, Madero-Pérez J, Swaney DL, Chang TS, Moritz M, Konrad C, Ward ME, Stevenson E, Hüttenhain R, Kauwe G, Mercedes M, Sweetland-Martin L, Chen X, Mok SA, Wong MY, Telpoukhovskaia M, Min SW, Wang C, Sohn PD, Martin J, Zhou Y, Luo W, Trojanowski JQ, Lee VMY, Gong S, Manfredi G, Coppola G, Krogan NJ, Geschwind DH, Gan L. Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration[J]. Cell, 2022, 185:712-728.e14. [18] Pascoal TA, Benedet AL, Ashton NJ, Kang MS, Therriault J, Chamoun M, Savard M, Lussier FZ, Tissot C, Karikari TK, Ottoy J, Mathotaarachchi S, Stevenson J, Massarweh G, Schöll M, de Leon MJ, Soucy JP, Edison P, Blennow K, Zetterberg H, Gauthier S, Rosa-Neto P. Microglial activation and tau propagate jointly across Braak stages[J]. Nat Med, 2021, 27:1592-1599. [19] Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, Nordberg A. Tau PET imaging in neurodegenerative tauopathies-still a challenge[J]. Mol Psychiatry, 2019, 24:1112-1134. [20] Colin M, Dujardin S, Schraen-Maschke S, Meno-Tetang G, Duyckaerts C, Courade JP, Buée L. From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy[J]. Acta Neuropathol, 2020, 139:3-25. |